
Opinion|Videos|November 8, 2023
Analysis of Infections and Humoral Immunity in Patients With RRMM Treated With Talquetamab Monotherapy in MonumenTAL-1
Author(s)Rafael Fonseca, MD
Dr Fonseca shares findings from the MonumenTAL-1 trial presented at ASCO 2023, suggesting potentially reduced infection rates in patients with relapsed/refractory multiple myeloma receiving talquetamab relative to BCMA-targeted agents.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5









































